Resource Summary Report

Generated by dkNET on Aug 1, 2026

FITC anti-human CD8

RRID:AB_1877178
Type: Antibody

Proper Citation

BioLegend Cat# 344704, RRID:AB_1877178

Antibody Information

URL: http://antibodyregistry.org/AB_1877178

Proper Citation: BioLegend Cat# 344704, RRID:AB_1877178

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_1877178

Vendor: BioLegend

Catalog Number: 344704

Alternative Catalog Numbers: 344703

Record Creation Time: 20250819T224513+0000

Record Last Update: 20250820T031205+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD8.

No alerts have been found for FITC anti-human CD8.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Zhang QS, et al. (2025) SHMT2 regulates CD8+ T cell senescence via the reactive oxygen species axis in HIV-1 infected patients on antiretroviral therapy. EBioMedicine, 112, 105533.

Wang X, et al. (2025) Machine-learning-assisted universal protein activation in living mice. Cell, 188(14), 3696.

Stockmann AP, et al. (2025) DF6215, an ?-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. Cell reports. Medicine, 102518.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Jia H, et al. (2025) A CCL5+CD20+CD8+ T cell subset drives pathogenic transformation of synoviocytes in rheumatoid arthritis via JAK-STAT signaling. Cell & bioscience, 16(1), 2.

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. Cell stem cell, 32(4), 529.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Le Y, et al. (2024) VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors. iScience, 27(1), 108731.

Deng Y, et al. (2024) Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages. Cell reports. Medicine, 5(4), 101489.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. Journal of

medical virology, 96(5), e29630.

Padoan B, et al. (2024) NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. Cell reports, 43(4), 114089.

Aoki H, et al. (2024) CD8+ T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance. Cell reports, 43(3), 113887.

Sugita Y, et al. (2024) Candidate tumor-specific CD8+ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis. Oncoimmunology, 13(1), 2371556.

Chiffelle J, et al. (2024) Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity, 57(10), 2466.

Morath K, et al. (2024) Activation-neutral gene editing of tonsillar CD4 T cells for functional studies in human ex vivo tonsil cultures. Cell reports methods, 4(1), 100685.

Jansen SA, et al. (2024) Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T cell behavior. iScience, 27(6), 110072.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research.

Kastenschmidt JM, et al. (2023) Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity, 56(8), 1910.